Prof Mejean presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from a trial in which 450 patients with metastatic renal cell carcinoma (mRCC) were randomised to receive either TKI inhibitor sunitinib alone or sunitinib and nephrectomy.

The trial found that survival between the two arms was no different, though it is noted that for patients ineligible for systemic treatment surgery remains the gold standard.

For more on these results, watch Dr Mejean discuss the findings with ecancer here, and read our news coverage here.

Slides from this presentation are available here.